0821 GMT - U.S. president Trump's pro-innovation stance could boost new drug discoveries, Novartis chief executive officer Vas Narasimhan tells CNBC at the World Economic Forum in Davos. "The Biden administration put in place some policies with the Inflation Reduction Act that were pretty damaging for the innovation ecosystem," Narasimhan says. Biden's IRA included Medicare's drug-price negotiation law, widely seen as negative by the industry. While the nomination of vaccine-skeptic Robert F. Kennedy Jr. to lead the country's health department poses a challenge for the sector, Narasimhan emphasizes the need to find common ground with the new administration, especially on preventing diseases like cancer and heart attacks. "There's obviously areas of disagreement, but I think overall, this is actually going to be a better environment for us than the past four years," Narasimhan says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 21, 2025 03:21 ET (08:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.